Fda grants agenus type b end-of-phase 2 meeting to discuss bot/bal therapy for relapsed or refractory metastatic colorectal cancer

Lexington, mass.--(business wire)--agenus inc. (“agenus”) (nasdaq: agen), a leader in discovering and developing novel immunological agents to treat various cancers, today announced it will conduct a type b end-of-phase 2 (eop2) meeting in july with the u.s. food and drug administration (fda) to discuss the botensilimab plus balstilimab (bot/bal) combination therapy studies in patients with relapsed/refractory metastatic colorectal cancer that is not msi-high or dmmr (r/r mss mcrc), as well as.
AGEN Ratings Summary
AGEN Quant Ranking